UA82503C2 - Жидкая композиция белка, который связывает фактор некроза опухолей - Google Patents

Жидкая композиция белка, который связывает фактор некроза опухолей Download PDF

Info

Publication number
UA82503C2
UA82503C2 UAA200508323A UA2005008323A UA82503C2 UA 82503 C2 UA82503 C2 UA 82503C2 UA A200508323 A UAA200508323 A UA A200508323A UA 2005008323 A UA2005008323 A UA 2005008323A UA 82503 C2 UA82503 C2 UA 82503C2
Authority
UA
Ukraine
Prior art keywords
composition according
tumor necrosis
necrosis factor
tme
buffer
Prior art date
Application number
UAA200508323A
Other languages
English (en)
Ukrainian (uk)
Inventor
Фабрицио Самаритани
Рио Алессандра Дель
Рита Агостинетто
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of UA82503C2 publication Critical patent/UA82503C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение касается стойкой фармацевтически приемлемой водной композиции TNF-связующего белка, который содержит ТВР-1 как TNF-связующий белок, буфер и изотонический агент, причем буфером является фосфатный буфер, который удерживает уровень рН в пределах от 6 до 7, а изотоническим агентом является хлорид натрия или маннит.
UAA200508323A 2003-02-28 2004-11-02 Жидкая композиция белка, который связывает фактор некроза опухолей UA82503C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03100505 2003-02-28
PCT/EP2004/050118 WO2004075918A1 (en) 2003-02-28 2004-02-11 Liquid formulations of tumor necrosis factor-binding proteins

Publications (1)

Publication Number Publication Date
UA82503C2 true UA82503C2 (ru) 2008-04-25

Family

ID=32921619

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200508323A UA82503C2 (ru) 2003-02-28 2004-11-02 Жидкая композиция белка, который связывает фактор некроза опухолей

Country Status (21)

Country Link
US (3) US8937045B2 (ru)
EP (1) EP1603596B1 (ru)
JP (1) JP4980048B2 (ru)
KR (1) KR20050105486A (ru)
CN (1) CN100563712C (ru)
AR (1) AR043418A1 (ru)
AT (1) ATE394123T1 (ru)
BR (1) BRPI0407649A (ru)
CA (1) CA2515539A1 (ru)
DE (1) DE602004013557D1 (ru)
EA (1) EA009079B1 (ru)
ES (1) ES2304602T3 (ru)
HR (1) HRP20050706A2 (ru)
IL (1) IL170414A (ru)
MX (1) MXPA05009135A (ru)
NO (1) NO20054440L (ru)
PL (1) PL213501B1 (ru)
RS (1) RS51041B (ru)
UA (1) UA82503C2 (ru)
WO (1) WO2004075918A1 (ru)
ZA (1) ZA200506504B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
TWI603739B (zh) 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
EA026226B1 (ru) * 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
AU2012326170B2 (en) 2011-10-18 2016-12-22 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
AU2012332767C1 (en) * 2011-10-31 2017-02-02 Genentech, Inc. Antibody formulations
WO2014011629A1 (en) 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Stable aqueous formulations of etanercept
KR102250937B1 (ko) 2012-09-11 2021-05-12 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
ES2806946T3 (es) 2012-10-26 2021-02-19 Lupin Atlantis Holdings Sa Composición farmacéutica estable de la proteína de fusión TNFR:Fc etanercept
CA2950873C (en) 2014-06-26 2022-08-23 Maruishi Pharmaceutical Co., Ltd. Rocuronium preparation with improved stability
RU2724900C1 (ru) * 2019-10-24 2020-06-26 Маруиси Фармасьютикал Ко., Лтд. Препарат рокурония с улучшенной стабильностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
NZ256293A (en) * 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
ES2171547T3 (es) * 1995-07-14 2002-09-16 Applied Research Systems Receptor de tnf y hormona esteroidica dhea en terapia combinada.
WO1997041895A2 (en) * 1996-05-08 1997-11-13 F. Hoffmann-La Roche Ag TREATMENT OF ASTHMA WITH TNFR-Ig
ATE247974T1 (de) * 1996-12-06 2003-09-15 Amgen Inc Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
CA2476934C (en) * 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine

Also Published As

Publication number Publication date
KR20050105486A (ko) 2005-11-04
HRP20050706A2 (en) 2005-12-31
DE602004013557D1 (de) 2008-06-19
US20070053906A1 (en) 2007-03-08
PL213501B1 (pl) 2013-03-29
WO2004075918A1 (en) 2004-09-10
ZA200506504B (en) 2006-12-27
MXPA05009135A (es) 2005-10-20
AU2004216483A1 (en) 2004-09-10
EP1603596B1 (en) 2008-05-07
US20150098950A1 (en) 2015-04-09
US9512215B2 (en) 2016-12-06
US8937045B2 (en) 2015-01-20
CA2515539A1 (en) 2004-09-10
HK1085677A1 (zh) 2006-09-01
ATE394123T1 (de) 2008-05-15
NO20054440L (no) 2005-09-26
EA200501230A1 (ru) 2006-04-28
RS20050662A (sr) 2007-11-15
IL170414A (en) 2009-11-18
PL378290A1 (pl) 2006-03-20
US20170020960A1 (en) 2017-01-26
JP2006519210A (ja) 2006-08-24
ES2304602T3 (es) 2008-10-16
CN1774266A (zh) 2006-05-17
AR043418A1 (es) 2005-07-27
EP1603596A1 (en) 2005-12-14
EA009079B1 (ru) 2007-10-26
JP4980048B2 (ja) 2012-07-18
CN100563712C (zh) 2009-12-02
RS51041B (sr) 2010-10-31
BRPI0407649A (pt) 2006-02-21

Similar Documents

Publication Publication Date Title
CA2649538C (en) Buffering agents for biopharmaceutical formulations
KR102100282B1 (ko) 항-프로락틴 수용체 항체 제제
AU2007307107B2 (en) Stable antibody formulations
EP4364724A2 (en) High concentration vegf receptor fusion protein containing formulations
KR20170005864A (ko) 액체 제약 조성물
KR102735988B1 (ko) 치료 항체 제제
EP3888678A1 (en) Anti-pd-l1 antibody preparation
EA009079B1 (ru) Жидкие составы фактор некроза опухоли-связывающих белков
CN101795670A (zh) G-csf的液体制剂
AU2012200284B2 (en) Stable Antibody Formulations
JP7548475B1 (ja) 抗体製剤
CN120754244B (zh) 一种含抗cd19抗体的药物组合物及其用途
CA3129901C (en) Therapeutic antibody formulation
AU2004216483B2 (en) Liquid formulations of tumor necrosis factor-binding proteins
KR20230026407A (ko) 액티빈 a 항체 제형 및 이의 사용 방법
AU2020364480A1 (en) Stable liquid composition, method for preparing same, and formulation comprising same
WO2014089957A1 (zh) 一种稳定的白消安注射剂
HK1085677B (en) Liquid formulations of tumor necrosis factor-binding proteins